Related Experiment Video

Updated: Aug 24, 2026

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart
09:38

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart

Published on: May 19, 2017

Protecting the myocardium: a role for the beta2 adrenergic receptor in the heart

Andrew J Patterson1, Weizhong Zhu, Amy Chow

  • 1Department of Anesthesia, Stanford University, Stanford, CA, USA. ajplanes@leland.stanford.edu

Critical Care Medicine
|April 9, 2004
PubMed
Abstract

Insights

Beta-2 adrenergic receptor (beta2AR) activation protects the heart by reducing cell death. This finding is crucial for understanding heart failure and developing new treatments.

Area of Science:

  • Cardiovascular physiology
  • Molecular pharmacology
  • Cell biology

Background:

  • The sympathetic nervous system, via beta adrenergic receptors (betaARs), influences cardiac function.
  • Chronic betaAR stimulation may worsen heart failure.
  • The distinct roles of beta1AR and beta2AR subtypes in cardiac health require clarification.

Purpose of the Study:

  • To investigate the individual effects of chronic beta1AR and beta2AR stimulation on cardiovascular function.
  • To determine the impact of betaAR subtype activation on myocyte apoptosis and mortality.

Main Methods:

  • Used beta1AR and beta2AR knockout mice and wild-type controls.
  • Administered continuous isoproterenol infusions for two weeks.
  • Assessed cardiac function, structure, myocyte apoptosis, and mortality.

Main Results:

  • Mice lacking beta2AR (beta2KO) showed significantly higher mortality rates after isoproterenol infusion.
  • Isoproterenol treatment led to increased myocyte apoptosis in beta2KO mice at 3 and 7 days.
  • No significant differences in mortality or apoptosis were observed in beta1KO mice.

Conclusions:

  • Beta-2 adrenergic receptor (beta2AR) activation in vivo demonstrates antiapoptotic effects.
  • beta2AR signaling contributes to myocardial protection.
  • Targeting beta2AR may offer therapeutic benefits in cardiovascular conditions.

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...